SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Two hands locked in a handshake cut by a pair of scissors, symbolizing a severed relationship or partnership. Black and white collage illustration on paper textured background
Neurodegenerative diseases
Takeda Breaks Up With Denali, Dumps Dementia Drug
Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Alzheimer’s disease, was previously discontinued after an FDA hold and disappointing early data.
April 6, 2026
 · 
2 min read
 · 
Tristan Manalac
Stethoscope with compass isolated on orange background. 3d illustration
Regulatory
Biotech Looks to Replimune RP1 Decision as ‘First Indicator’ of FDA Direction
The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency’s future regulatory decision-making, analysts say, with implications stretching well beyond one company.
April 6, 2026
 · 
5 min read
 · 
Ben Hargreaves
Doubtful person, hands on hips, choosing the way as multiple arrows on the road showing a mess of different directions. Choosing the correct pathway, difficult decision concept, confusion symbol.
FDA
FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls
While recent FDA guidance speaks to the agency’s support of innovative trial designs—including the use of external controls—the application of this flexibility appears to be inconsistent. One former regulator says the situation is more nuanced.
April 6, 2026
 · 
6 min read
 · 
Heather McKenzie
IN PARTNERSHIP WITH API
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early testing, smart IP and regulatory planning, and scalable CMC choices can help founders reach first-in-human faster.
April 6, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Vector illustration of a businessman unplugging polluted factory
Manufacturing
BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot
BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S.
April 3, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Abstract financial chart with stock graph market.Vector illustration
Tariffs
Trump Hits Drugmakers With 100% Tariff but Carve-outs Soften the Blow
While some large companies could start paying the full tariff in 120 days, many products, including orphan drugs, cell and gene therapies, and antibody-drug conjugates, will enjoy exemptions that waive or greatly reduce the levies.
April 3, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Cartoon high-speed train in the white background, 3d rendering. Digital drawing.
Mergers & acquisitions
Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts
After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M&A action from other big names, including Novartis, Amgen and AbbVie.
April 3, 2026
 · 
3 min read
 · 
Annalee Armstrong
Business concept, vector illustrations
Weight loss
Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences
After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since January.
April 2, 2026
 · 
3 min read
 · 
Annalee Armstrong
Control, Fluctuation, Uncertainty, Businessman balancing with an umbrella
Rare diseases
Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor
With CBER director Vinay Prasad set to depart the agency at the end of the month, a coalition of patient groups and biotech executives penned a letter imploring the Trump administration to “restore regulatory clarity” for rare disease therapies. Experts on a BioSpace panel last week also acknowledged the challenges faced by a more stringent FDA.
April 2, 2026
 · 
6 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS